Welcome to our dedicated page for iShares Biotechnology ETF news (Ticker: IBB), a resource for investors and traders seeking the latest updates and insights on iShares Biotechnology ETF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect iShares Biotechnology ETF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of iShares Biotechnology ETF's position in the market.
Curis, Inc. (NASDAQ: CRIS) has been added to the Nasdaq Biotechnology Index and the iShares Biotechnology ETF, effective before market open on December 20, 2021. Curis focuses on innovative cancer therapeutics, with ongoing clinical trials for several drug candidates, including CA-4948, which has received Orphan Drug Designation for acute myeloid leukemia. The company collaborates with Aurigene and ImmuNext, and their partnership with Genentech commercializes Erivedge for advanced basal cell carcinoma.
BlackRock announced product enhancements to two iShares ETFs, effective around June 21, 2021. The iShares Nasdaq Biotechnology ETF (IBB) will transition to track the ICE Biotechnology Index and will be renamed as iShares Biotechnology ETF. Similarly, the iShares PHLX Semiconductor ETF (SOXX) will now track the ICE Semiconductor Index and change its name to iShares Semiconductor ETF. Investors in these ETFs need not take any action, and no capital gains distributions are expected from this transition.
FAQ
What is the current stock price of iShares Biotechnology ETF (IBB)?
What is the market cap of iShares Biotechnology ETF (IBB)?
